DiaMedica Therapeutics Inc. Accrued Professional Fees, Current
DiaMedica Therapeutics Inc. (DMAC) had Accrued Professional Fees, Current of $165.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-08-10
- 2026-06-30: Accrued Professional Fees, Current $165.00K.
- 2026-03-31: Accrued Professional Fees, Current $64.00K.
- 2025-12-31: Accrued Professional Fees, Current $120.00K.
- 2025-09-30: Accrued Professional Fees, Current $97.00K.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2026-06-30 | $165.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $64.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $120.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $97.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $94.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $82.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $112.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $91.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $155.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $150.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $98.00K 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |